Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

Everolimus 5pembrolizumab 2cabozantinib 2Trastuzumab 2Nivolumab 2vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1spartalizumab 1romidepsin 1regorafenib 1pentetreotide 1guadecitabine 1fostamatinib 1exemestane 1entrectinib 1entinostat 1belzutifan 1avelumab 1alectinib 1Vinorelbine 1Sirolimus 1Rosiglitazone 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Nephrectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × guadecitabine × Endocrine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡